3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR* -5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a -hexadecahydro-5, 19-dihydroxy -3-[2-(4-hydroxy-3-methoxycyclohexyl) -1-methylethenyl]-14,16-dimethoxy -4,10,12,18-tetramethyl-8-(2-propenyl) -15,19-epoxy-3H-pyrido[2,1-c] [1,4] oxaazacyclotricosine-1,7,20,21(4H,23H) -tetrone, monohydrate
|
Carbamazepine, caspofungin, fosphenytoin, phenobarbital, phenytoin, rifabutin, rifampin, sirolimus, St. John's wort
Tacrolimus blood concentrations may be reduced, increasing the risk of transplant rejection. CYP3A4 inhibitors (eg, cimetidine, erythromycin, ketoconazole)
Use with caution during topical administration. Ethanol
Risk of facial flushing may be increased with topical tacrolimus. Hydantoins (eg, phenytoin)
Tacrolimus plasma levels may be reduced, while hydantoin concentrations may be increased. Mycophenolate mofetil, sildenafil, simvastatin
Plasma levels may be elevated by tacrolimus, increasing the risk of adverse reactions. Nephrotoxic agents (eg, aminoglycosides, amphotericin B, cisplatin, cyclosporine)
Additive nephrotoxicity. Potassium-sparing diuretics
Avoid use with tacrolimus because of the potential for tacrolimus to cause hyperkalemia
|